Medical Prognosis Overview

  • Founded
  • 2004
  • Status
  • Public
  • Employees
  • 16
  • Stock Symbol
  • ALLR
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $0.11
  • (As of Friday Closing)

Medical Prognosis General Information


Allarity Therapeutics AS is a late clinical-stage, precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers guided by its proprietary drug response predictor technology, the DRP platform. The product portfolio includes stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; dovitinib, a pan-TKI in post-Phase 3 for renal cell carcinoma; IXEMPRA (ixabepilone), a microtubulin inhibitor for the treatment of breast cancer; LiPlaCis, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and irofulven, a DNA damaging agent in Phase 2 for prostate cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Industries
Drug Discovery
Stock Exchange
Primary Office
  • Venlighedsvej 1
  • 2970 Hørsholm
  • Denmark
+45 21 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medical Prognosis Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.11 $0.11 $0.07 - $0.26 $24.3M 220M 4.27M -$0.20

Medical Prognosis Financials Summary

In Thousands,
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 40,507 21,743 36,655 32,928
Revenue 42 120 340 780
EBITDA (20,379) (10,016) (3,290) (4,686)
Net Income (15,239) (19,785) (2,365) (4,607)
Total Assets 27,091 27,166 38,527 2,093
Total Debt 493 963 2,894 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Medical Prognosis Executive Team (2)

Name Title Board Seat Contact Info
Steve Carchedi Chief Executive Officer
Jens Knudsen Chief Financial Officer
To view Medical Prognosis’s complete executive team members history, request access »

Medical Prognosis Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medical Prognosis Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000000 0 13-Jul-2020 000000000000000000 00.000 Drug Discovery 00000 00000000
Oncology Venture Sweden 24-Aug-2018 Merger/Acquisition Drug Discovery
To view Medical Prognosis’s complete acquisitions history, request access »

Medical Prognosis Subsidiaries (1)

Company Name Industry Location Founded
00000000 0000000 0 Drug Discovery Hørsholm, Denmark 0000
To view Medical Prognosis’s complete subsidiaries history, request access »